Precision Medicine in Oncology® | Specialty

The OncLive Precision Medicine in Oncology® condition center page is a comprehensive resource for clinical news and expert insights on precision-focused approaches in patients with cancer, with gene-targeted tyrosine kinase inhibitors and antibody-drug conjugates, checkpoint inhibitors, tumor-infiltrating lymphocyte therapy, and other tailored treatments. This page features news articles, interviews in written and video format, and podcasts that focus on updates and ongoing research with personalized therapies across solid and hematologic tumors.

Gutierrez Provides Insight on Bridging Gaps in Cancer Care

October 12th 2020

In our exclusive interview, Rodolfo Gutierrez, MD, discusses the issues that surround access to care and clinical outcomes with Hispanic patients, efforts The Angeles Clinic has spearheaded to bridge this gap in care, and the importance of patient and provider education and awareness.

Family History Plays Key Role in Germline Testing for Hereditary Breast and Ovarian Cancers

October 12th 2020

Sofia D. Merajver, MD, PhD, discusses the importance of germline testing in patients with breast and ovarian cancer along with how this testing is being used to personalize treatment.

Identifying Genetic Variants, Matching With Targeted Therapies Serve as Next Great Challenge With Germline Testing in Oncology

October 12th 2020

Goutham Narla, MD, PhD, discusses the revolution of genetic testing and how it has led to more accurate and widespread assays for patients with cancer.

Patient Advocacy and Education Are Essential for Optimal Cancer Care

October 11th 2020

Caroline Farrington, PhD, shares her insight as both a researcher and a cancer survivor on the importance of patient advocacy, as well as the proper resources to aid patients through a cancer diagnosis.

Focusing on the Future of Genetic Testing in Oncology

October 10th 2020

John M. Carethers, MD, MACP, discusses recent developments in multi-gene panel testing.

Dr. Yap on the Rationale for the SEASTAR Trial in Advanced Solid Tumors

October 8th 2020

Timothy Yap, MBBS, PhD, FRCP, discusses the rationale for the ongoing phase 1b/2 SEASTAR trial in advanced solid tumors.

Subbiah Tempers Concerns Regarding Pembrolizumab Approval in TMB-High Solid Tumors

October 8th 2020

In our exclusive interview, Vivek Subbiah, MD, discusses the FDA approval of pembrolizumab in tumor mutational burden–high solid tumors, shares the “transformative importance” of the regulatory decision, and speaks to the controversy surrounding the approval.

Mobocertinib Continues to Show Clinical Activity in EGFR Exon 20–Mutant NSCLC

October 5th 2020

Mobocertinib elicited a 43% objective response rate and an 86% disease control rate in select patients with non–small cell lung cancer who have EGFR exon 20 insertion mutations.

Stoffel Underscores Importance of Germline Testing for Lynch Syndrome

October 2nd 2020

Elena M. Stoffel, MD, MPH, discusses the importance of genetic testing in detecting Lynch syndrome and other hereditary syndromes associated with risk of colorectal cancer and other diseases.

Precision Medicine Picks up Pace Across Oncology

September 28th 2020

Andre Goy, MD, MS, discusses how matching the right treatment with the right patient resides at the heart of precision medicine, but with continued interest in pursuing the molecular milieu of cancers, precision medicine has the potential to better inform pre- and post-cancer interventions as well.

Leveraging Immunotherapy and Targeted Therapy for Cure in Lung Cancer

September 26th 2020

Efforts to leverage targeted therapy and immunotherapy, which have been approved modalities in advanced non–small cell lung cancer, are leading to improved survival in patients with advanced and earlier-stage disease.

Dr. Goy on Updates in Precision Medicine in Oncology

September 26th 2020

Andre Goy, MD, MS, discusses updates in precision medicine.

Today’s Molecular Profiling Efforts Will Define the New Decade of GI Cancer Management

September 26th 2020

Over the past decade in gastrointestinal cancer treatment, the acknowledgement that cancer is heterogeneous and likely polyclonal has prompted a shift from gene testing for some patients, to many patients.

Dr. Levy on the DFS Benefit Achieved With Adjuvant Osimertinib in EGFR+ NSCLC

September 25th 2020

Benjamin P. Levy, MD, discusses the disease-free survival benefit with adjuvant osimertinib in the phase 3 ADAURA trial.

Dr. Vokes on Investigative Biomarkers of Response to Checkpoint Inhibitors in Cancer

September 25th 2020

Natalie I. U. Vokes, MD, discusses investigative biomarkers of response to checkpoint inhibitors in the field of oncology.

Study Endorses Benefits of Population-Based BRCA Screening

September 24th 2020

Implementing population-based BRCA1/2 testing is not only cost-effective in high- and upper middle–income countries but could also prevent tens of thousands of breast and ovarian cancer cases compared with the current clinical strategy, which recommends testing only for high-risk women.

First-Line Apatinib/Gefitinib Combo Shows Significant Benefit for EGFR-Mutant NSCLC

September 20th 2020

Dual inhibition of both VEGFR and EGFR with the combination of apatinib and gefitinib in the first-line treatment of patients with advanced EGFR-mutant non–small cell lung cancer demonstrated superior progression-free survival.

Entrectinib Shows Intracranial Response in NTRK+ Tumors and CNS Metastases

September 20th 2020

Entrectinib demonstrated durable intracranial activity in a small subset of patients with NTRK fusion–positive solid tumors and baseline central nervous system metastases.

Sequencing and Resistance Mechanism Challenges Arise in Biomarker-Driven NSCLC

September 15th 2020

Kartik Konduri, MD, discussed current treatment options that are available for patients with ALK, ROS1, and RET–positive NSCLC, as well as promising agents in the pipeline.

Giri and Gomella on Fostering a New Framework for Genetic Testing Guidelines in Prostate Cancer

September 14th 2020

In our exclusive interview, Dr. Giri and Dr. Gomella discuss the rationale to create the first multidisciplinary, consensus-driven framework for prostate cancer genetic testing, the importance of having a multidisciplinary team weigh in on the recommendations, and key aspects of the guidelines that could have clinical implications for men in this space.